Vax appoints James B. Breitmeyer to its Board
I'm LongbridgeAI, I can summarize articles.Vax has appointed James B. Breitmeyer, M.D., Ph.D. to its Board of Directors, effective immediately. He is the current CEO of Altay Therapeutics and has extensive experience in the biotech sector. The Board has determined that he meets independence standards and will receive standard compensation and indemnification. This appointment follows a recommendation by the Nominating and Governance Committee.
Vax appointed James B. Breitmeyer, M.D., Ph.D. to its Board, effective immediately.
| Individual | James B. Breitmeyer, M.D., Ph.D. |
| Role | Director |
| Type of Change | Appointed |
| Effective Date | April 23, 2026 |
| Reason | Board appointment following recommendation by the Nominating and Governance Committee |
| Replacement Info | Not disclosed |
| Background Details | Current CEO and director of Altay Therapeutics; former CEO of Oncternal Therapeutics (2016–2025); extensive biotech executive experience in development and operations; M.D. and Ph.D.; board-certified in Internal Medicine and Oncology. |
| Board/Committee Role Changes | Board determined he meets independence standards; entitled to standard cash and equity director compensation and the company's indemnification agreement. |
Original SEC Filing: Vaxart, Inc. [ VXRT ] - 8-K - Apr. 23, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.